DOI: https://doi.org/10.18621/eurj.1418269

Orthopedics and Traumatology

## The economic impact of two-stage knee arthroplasty revisions: a projection for a specialized health center in Türkiye

Alparslan Yurtbay<sup>1</sup>, Ahmet Ersoy<sup>2</sup>, Cahit Şemsi Şay<sup>3</sup>, Ferhat Say<sup>3</sup>

<sup>1</sup>Department of Orthopedics and Traumatology, Samsun University, Faculty of Medicine, Samsun, Türkiye, <sup>2</sup>Department of Orthopedics and Traumatology, Turhal State Hospital, Tokat, Türkiye, <sup>3</sup>Department of Orthopedics and Traumatology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Türkiye

## ABSTRACT

**Objectives:** The increase in the number of arthroplasty surgeries worldwide also leads to an increase in revision surgeries. This study examines the costs of primary and revision arthroplasty treatments in a tertiary university hospital's orthopedics and traumatology clinic. It also explores the impact of revision surgeries on the healthcare system.

**Methods:** Seventy-six patients who had total knee arthroplasty at a university hospital between 01.01.2017 and 30.09.2022 were included in the study. The patients were divided into three groups: primary (n=25), aseptic reasons one-stage revision (n=27), and septic reasons two-stage revisions (n=24). For each patient included in the study, detailed documents regarding medical supplies, anesthesia, operating room, intensive care, consultation, medicine/serum, medical treatment, laboratory, blood and blood products, microbiology, radiology, food, bed, and attendant fees were provided separately by the hospital purchasing and statistics departments. **Results:** When comparing the costs of primary, one-stage revision, and two-stage revision surgeries, the average costs were 5689 Turkish Lira ( $\pounds$ ), 8294.97  $\pounds$ , and 40919.67  $\pounds$ , respectively. In patients with septic reasons, the group that underwent two-stage revisions had significantly higher costs than the aseptic group in terms of surgery time, hospital stay duration, medication, treatment, surgery, anesthesia, intensive care, laboratory tests, imaging, blood center services, consultations, visits, meal expenses, and invoiced amount (P<0.001).

**Conclusion:** Preventing and treating periprosthetic infections is costly and challenging. We need more research to develop effective protocols and reduce costs. As the number of patients undergoing knee arthroplasty is expected to rise, healthcare systems must ensure the sustainability of public financial resources, especially in public university hospitals.

Keywords: Arthroplasty, knee replacement, revision, cost analysis, hospital economics

steoarthritis continues to be an essential public health problem worldwide [1]. Due to the population's increasing age and expectations from daily life, the number of prosthetic joint replacement operations is increasing daily. Since the demand for joint arthroplasty is expected to increase significantly

Corresponding author: Alparslan Yurtbay, MD., Assist. Prof., Phone: +90 362 313 00 55, E-mail: yurtbayalparslan@gmail.com

**How to cite this article:** Yurtbay A, Ersoy A, Şay CŞ, Say F. The economic impact of two-stage knee arthroplasty revisions: a projection for a specialized health center in Türkiye. Eur Res J. 2024;10(6):600-608. doi: 10.18621/eurj.1418269

Received: January 11, 2024 Accepted: March 16, 2024 Published Online: May 10, 2024



Copyright © 2024 by Prusa Medical Publishing Available at https://dergipark.org.tr/en/pub/eurj



This is an open access article distributed under the terms of Creative CommonAttribution-NonCommercial-NoDerivatives 4.0 International License

in the coming years, it is natural to expect that the number of knee revisions and the economic burden of prosthetic infections will increase over the years [2]. In a study conducted in Germany, the number of geriatric patients is expected to increase in the coming years, and the use of orthopedic implants will increase rapidly. The same study predicted that the incidence of total knee arthroplasty (TKA) operations would increase by 43%, and a total of 225,957 TKA procedures will be applied in 2050. In addition, it is predicted that annual TKA revision operations will increase rapidly by 90% [3].

The increase in the elderly group and the number of applied prostheses increase the number of implant failures. The most common causes of implant failure and need for revision are instability, mechanical loosening, incorrect prosthesis positioning, dislocation, polyethylene wear, periprosthetic fractures, and infection [4]. Periprosthetic infection is a very devastating complication that increases the time and cost of treatment. The infection rate in knee arthroplasty ranges from 0,4% to 2% in primary total knee replacement and 5,6% in revisions [5]. Prosthetic joint infections (PJIs) have increased, as is obvious, and we anticipate that this trend will continue as more primary joints are replaced.

Two-stage revision is the most commonly used treatment method worldwide in treating infected hip and knee arthroplasty [6]. In the first stage, the infected prosthesis is removed. The local antibiotic release aims to fill the formed space with antibiotic bone cement (spacer). At the same time, systemic infection control is tried to be achieved with intravenous (IV) antibiotics. After infection control is ensured with antibiotics lasting an average of 4 months (2-6 months), the spacer is removed, and the final treatment is implant placement. During all this time, patients undergo a very costly treatment process, considering prolonged hospitalizations, long-term drug treatments, and at least two operations.

Parallel to the increasing number of arthroplasty cases, revision due to aseptic loosening and two-stage revision cases due to periprosthetic infection are also increasing. The cost of managing knee revisions is expected to increase as an issue for patients, physicians, and healthcare institutions [7]. Recent research on this subject is limited because the stated costs are estimated costs. Readmissions, prolonged hospital stays, long-term medication use, and prolonged post-operative rehabilitation times account for many of these high costs. However, more evidence-based information is needed to support these measurements [8]. Existing studies have limitations because they either report estimates rather than actual costs, provide no comparison group (such as cases of non-infected primary total knee arthroplasty), or sum up all orthopedic surgery cases rather than report on specific procedures [9-11]. Furthermore, many of these studies needed to analyze the factors contributing to higher costs beyond repeated operations.

This study compared primary arthroplasty operations, revision operations due to aseptic loosening, and two-stage revision procedures due to periprosthetic infection. Our main aim is to determine the costs of certain services such as pharmaceutical services (inpatient and outpatient treatment), medical and surgical supplies, anesthesia services, diagnostic and radiographic evaluations, operating room services, laboratory costs, blood products, and consultation services in these groups.

#### **METHODS**

This study was conducted at a single specialized tertiary care center between January 1, 2017, and December 31, 2022. Patient medical records and infection monitoring database were reviewed for 524 patients who underwent total knee arthroplasty in our institution. The patients were followed for one year from the first surgery date. Institutional review board approval was obtained to analyze patient records and data from the current study (approval number: E-15374210-010.06.99-349814).

A total of 76 patients were included in the study and were divided into three separate groups. In the first group, with the help of a computer-generated program, a study group of 25 primary total knee arthroplasty with no infection matched in terms of type of surgical procedure, date of surgery, age, and gender parameters was formed. In the second group, 27 patients who underwent revision surgery due to radiological aseptic loosening in Ewald and did not develop complications in their follow-up were included. Aseptic loosening criteria, as stated in Ewald, 1) radiolucent lines <2 mm regardless of their localization and progression, 2) the presence of radiolucent lines reaching the tibial plateau surface, 3) radiolucent lines in the tibial zone 5-6-7, 4) progressive radiolucent lines are has been accepted [12]. The third group consisted of 24 patients who had only deep or joint cavity infections and needed a two-stage revision following their primary procedure. A new definition of PJI has recently been proposed by the European Bone and Joint Infection Society (EBJIS) [13]. Based on this definition, only deep infections characterized by extension into the joint space or deep fascial layers were included in the study. This group did not include patients who underwent debridement and washing due to early postoperative infection and superficial infections. There were no deaths for all three cohorts in our study.

Post-operative care is standard for all patients and includes post-operative dressing with iodine solution at intervals of 48 hours, pain control, empirical antibiotic therapy, use of pharmaceutical agents for anti-embolic prosody, and physical therapy and rehabilitation studies.

The detailed documents of the operation costs, anesthesia, and operating room costs, consultation costs, pharmaceutical agents costs, laboratory costs, blood center expenses, microbiology expenses, radiology expenses, and bed and attendant fees of the patients included in the study were obtained from the purchasing and statistics department of our hospital. Operating room costs include implants, intravenous solutions, surgical supplies, and post-operative recovery. Fees are charged to the laboratory for biochemistry, hematology, urology, immunology, microbiology, and histological specimen processing. Radiology costs include x-rays, ultrasound, computed tomography, and magnetic resonance imaging scans. The consultation fees obtained in this study include those from pulmonology, cardiology, and other internal branches in inpatient and outpatient settings.

#### **Statistical Analysis**

Microsoft Excel spreadsheet program (Version 2013, Microsoft Corporation) was used for data collection, comparison, and calculations. Statistical analysis of the study's data was performed using the SPSS for Windows 23.0 program (SPSS Inc). The mean, standard deviation, median lowest, highest, frequency, and ratio values were used in the descriptive statistics. The distribution of the variables was meas-

ured using the Kolmogorov-Smirnov test. In the comparison of two independent groups showing normal distribution, two Independent t-tests were performed, and One-way Analysis of Variance (One-Way ANOVA) was used to compare more than two groups. The Kruskal–Wallis H test was performed to investigate differences between more than two independent groups that did not conform to normal distribution. When there was a difference between the groups, to determine from which group or groups this difference originated, the Mann–Whitney U test was used to compare the two groups. The chi-squared test was used for categorical variables. Statistical significance was set at a P-value of less than 0.05.

#### **RESULTS**

Out of the 76 patients, 60.5% were female and 39.5% were men. The mean age was  $65.5\pm16$  years. While 7 (28%) of 25 patients who underwent primary arthroplasty were smoking, 6 (22.2%) of 27 patients who underwent one-stage revision were smokers. Of the 24 patients who underwent two-stage revision, 8 (33.3%) were smokers. There was no statistical difference between the groups (P=0.78).

The age and sex distribution did not differ significantly in the aseptic and septic groups (P>0.05) (Table 1). In the septic group, length of stay, surgery time, service expenses, drug, laboratory, radiology, operation-anesthesia, blood and blood product, consulting, intensive care, and policlinic expenses were significantly higher than the aseptic group (P<0.001) (Table 2).

The median hospital stay was 21 (min 2 and max 42) days in the group that underwent two-stage revision surgery due to periprosthetic knee infection, and this duration was significantly higher than 3.5 days (between 2-8 days) in the group that underwent primary total knee arthroplasty (P<0.001).

The mean number of readmissions in the twostage knee revision group was 5.6 (range, 2 to 9), the mean was 2.4 in the single-stage knee revision group (range, 2 to 4), and the mean in the primary total knee arthroplasty group was 0.12 (range, 0 to 2) (P<0.001).

When the hospitalization and service fees of the patients in the groups were compared, it was found that the average of 112.39 Turkish Lira ( $\pounds$ ) in the primary arthroplasty group, 222.15  $\pounds$  in the patients who

Age (years) $65\pm16$ $58$ (40-81)         Gender       (40-81)         Female       46 (60%)         Male       30 (40%)         Cigarette       (30 (40%))         Use       16 (21%)         Not Use       60 (79%)         Length of stay (days) $23\pm19$ 21 (3-42)         Surgery time (min) $209.34\pm86.42$ 150 (90-300)         Service expenses $1889\pm1258$ 350 (78-12150)         Drug expenditures $1841\pm313$ 1370 (88.9-2876)         Laboratory expenses $258.54\pm205$ 124 (32-530)         Radiology expenses $90.2\pm45.4$ 98 (39-156)         Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)         Blood and blood product expenses $1653.54\pm1664$ 461 (14.3745.8)         Consulting expenses $261.75\pm260$ 42 (0-580.99)         Intensive care $414.78\pm367$ $420$ (0-580.99)         Intensive care $414.78\pm367$ $420$ (0-780)         Policlinic $148.88\pm93.14$ $111$ (30-286)	Characteristisc	Data		
Gender         Image: Second sec	Age (years)	65±16		
Female         46 (60%)           Male         30 (40%)           Cigarette         30 (40%)           Use         16 (21%)           Not Use         60 (79%)           Length of stay (days)         23±19         21 (3-42)           Surgery time (min)         209.34±86.42         150 (90-300)           Service expenses         1889±1258         350 (78-12150)           Drug expenditures         1841±313         1370 (88.9-2876)           Laboratory expenses         258.54±205         124 (30-99-156)           Operation, anesthesia expenses         19045.74±12012         18622 (3650-32678.88)           Blood and blood product expenses         1653.54±1664         461 (14-3745.8)           Consulting expenses         261.75±260         42 (0-780)           Intensive care         414.78±367         420 (0-780)           Policlinic         148.88±93.14         111 (30-286)			(40-81)	
Male $30 (40\%)$ Cigarctte       16 (21%)         Use       16 (21%)         Not Use       60 (79%)         Length of stay (days) $23\pm19$ 21       (3-42)         Surgery time (min)       209.34 $\pm$ 86.42       150         Surgery time (min)       208.54 $\pm$ 205       124         Surgery time (min)       148.74 $\pm$ 12012       18622         Radiology expenses       19045.74 $\pm$ 12012       18622         (3650-32678.88)       180       181         Blood and blood product expenses       1653.54 $\pm$ 1664       461         (14.3745.8)       (0-580.99)       111         Intensive care       414.78 $\pm$ 367       420	Gender			
Cigarette         Use       16 (21%)         Not Use       60 (79%)         Length of stay (days) $23\pm19$ $21$ (3-42)       (3-42)         Surgery time (min) $209.34\pm86.42$ 150         (90-300)       (90-300)         Service expenses $1889\pm1258$ $350$ Drug expenditures $1841\pm313$ $1370$ (88-9-2876)       124       (32-530)         Laboratory expenses $90.2\pm45.4$ $98$ (30-986) $(32-530)$ (32-530)         Radiology expenses $90.2\pm45.4$ $98$ (30-986) $(14-3745.8)$ (350-32678.88)         Blood and blood product expenses $1653.54\pm1664$ 461         (14-3745.8)       (0-580.99)       (0-580.99)         Intensive care $414.78\pm367$ $420$ (0-780)       (0-780)       (0-780)	Female	46 (60%)		
Use16 (21%)Not Use60 (79%)Length of stay (days) $23\pm19$ $21$ (3-42)Surgery time (min) $209.34\pm86.42$ 150 (90-300)Service expenses $1889\pm1258$ $350$ (78-12150)Drug expenditures $1841\pm313$ $1370$ (88.9-2876)Laboratory expenses $258.54\pm205$ $124$ (32-530)Radiology expenses $90.2\pm45.4$ $98$ (39.99-156)Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)Blood and blood product expenses $261.75\pm260$ $42$ (0-580.99)Intensive care $414.78\pm367$ $420$ (0-780)Policlinic $148.88\pm93.14$ $111$ (30-286)	Male	30 (40%)		
Not Use $60(79\%)$ Length of stay (days) $23\pm19$ $21$ (3-42)Surgery time (min) $209.34\pm86.42$ $150$ (90-300)Service expenses $1889\pm1258$ $350$ (78-12150)Drug expenditures $1841\pm313$ $1370$ (88.9-2876)Laboratory expenses $258.54\pm205$ $124$ (32-530)Radiology expenses $90.2\pm45.4$ $98$ (39.99-156)Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)Blood and blood product expenses $1653.54\pm1664$ $461$ (14-3745.8)Consulting expenses $261.75\pm260$ $42$ (0-580.99)Intensive care $414.78\pm367$ $420$ 	Cigarette			
Length of stay (days) $23\pm19$ $21$ (3-42)Surgery time (min) $209.34\pm86.42$ $150$ (90-300)Service expenses $1889\pm1258$ $350$ (78-12150)Drug expenditures $1841\pm313$ $1370$ (88.9-2876)Laboratory expenses $258.54\pm205$ $124$ (32-530)Radiology expenses $90.2\pm45.4$ $98$ (39.99-156)Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)Blood and blood product expenses $1653.54\pm1664$ $461$ (14-3745.8)Consulting expenses $261.75\pm260$ $42$ (0-580.99)Intensive care $414.78\pm367$ $420$ (0-780)Policlinic $148.88\pm93.14$ $111$ (30-286)	Use	16 (21%)		
$(3-42)$ Surgery time (min) $209.34\pm86.42$ $150$ (90-300)Service expenses $1889\pm1258$ $350$ (78-12150)Drug expenditures $1841\pm313$ $1370$ (88.9-2876)Laboratory expenses $258.54\pm205$ $124$ (32-530)Radiology expenses $90.2\pm45.4$ $98$ (39.99-156)Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)Blood and blood product expenses $1653.54\pm1664$ $461$ (14-3745.8)Consulting expenses $261.75\pm260$ $42$ (0-580.99)Intensive care $414.78\pm367$ $420$ (0-780)Policlinic $148.88\pm93.14$ $111$ (30-286)	Not Use	60 (79%)		
Surgery time (min)         209.34±86.42         150 (90-300)           Service expenses         1889±1258         350 (78-12150)           Drug expenditures         1841±313         1370 (88.9-2876)           Laboratory expenses         258.54±205         124 (32-530)           Radiology expenses         90.2±45.4         98 (39.99-156)           Operation, anesthesia expenses         19045.74±12012         18622 (3650-32678.88)           Blood and blood product expenses         1653.54±1664         461 (14-3745.8)           Consulting expenses         261.75±260         42 (0-580.99)           Intensive care         414.78±367         420 (0-780)           Policlinic         148.88±93.14         111 (30-286)	Length of stay (days)	23±19	21	
			(3-42)	
Service expenses $1889\pm1258$ $350$ (78-12150)           Drug expenditures $1841\pm313$ $1370$ (88.9-2876)           Laboratory expenses $258.54\pm205$ $124$ (32-530)           Radiology expenses $90.2\pm45.4$ $98$ (39.99-156)           Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)           Blood and blood product expenses $1653.54\pm1664$ $461$ ( $14-3745.8$ )           Consulting expenses $261.75\pm260$ $42$ ( $0-580.99$ )           Intensive care $414.78\pm367$ $420$ ( $0-780$ )           Policlinic $148.88\pm93.14$ $111$ ( $30-286$ )	Surgery time (min)	209.34±86.42	150	
$(78-12150)$ Drug expenditures $1841\pm313$ $1370$ (88.9-2876)         Laboratory expenses $258.54\pm205$ $124$ (32-530)         Radiology expenses $90.2\pm45.4$ $98$ (39.99-156)         Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)         Blood and blood product expenses $1063.54\pm1664$ $461$ ( $14-3745.8$ )         Consulting expenses $261.75\pm260$ $42$ ( $0-580.99$ )         Intensive care $414.78\pm367$ $420$ ( $0-780$ )         Policlinic $148.88\pm93.14$ $111$ ( $30-286$ )			(90-300)	
Drug expenditures $1841\pm313$ $1370$ (88.9-2876)         Laboratory expenses $258.54\pm205$ $124$ (32-530)         Radiology expenses $90.2\pm45.4$ $98$ (39.99-156)         Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)         Blood and blood product expenses $1653.54\pm1664$ $461$ (14-3745.8)         Consulting expenses $261.75\pm260$ $42$ (0-580.99)         Intensive care $414.78\pm367$ $420$ (0-780)         Policlinic $148.88\pm93.14$ $111$ (30-286)	Service expenses	$1889 \pm 1258$		
(88.9-2876)         Laboratory expenses $258.54\pm205$ $124$ (32-530)       (39.99-156)         Operation, anesthesia expenses $990.2\pm45.4$ $98$ (30-99-156)       (3650-32678.88)         Blood and blood product expenses $1653.54\pm1664$ $461$ (14-3745.8)       (14-3745.8)         Consulting expenses $261.75\pm260$ $42$ (0-580.99)       (0-580.99)         Intensive care $414.78\pm367$ $420$ (0-780)       (0-780)         Policlinic $148.88\pm93.14$ $111$			(78-12150)	
Laboratory expenses $258.54\pm205$ $124$ (32-530)         Radiology expenses $90.2\pm45.4$ $98$ (39.99-156)         Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)         Blood and blood product expenses $1653.54\pm1664$ $461$ (14-3745.8)         Consulting expenses $261.75\pm260$ $42$ (0-580.99)         Intensive care $414.78\pm367$ $420$ (0-780)         Policlinic $148.88\pm93.14$ $111$ (30-286)	Drug expenditures	1841±313		
(32-530)Radiology expenses $90.2\pm45.4$ $98$ (39.99-156)Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)Blood and blood product expenses $1653.54\pm1664$ $461$ (14-3745.8)Consulting expenses $261.75\pm260$ $42$ (0-580.99)Intensive care $414.78\pm367$ $420$ (0-780)Policlinic $148.88\pm93.14$ $111$ (30-286)			· · ·	
Radiology expenses $90.2\pm45.4$ $98$ (39.99-156)Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)Blood and blood product expenses $1653.54\pm1664$ $461$ (14-3745.8)Consulting expenses $261.75\pm260$ $42$ (0-580.99)Intensive care $414.78\pm367$ $420$ (0-780)Policlinic $148.88\pm93.14$ $111$ (30-286)	Laboratory expenses	$258.54{\pm}205$		
(39.99-156)         Operation, anesthesia expenses       19045.74±12012       18622 (3650-32678.88)         Blood and blood product expenses       1653.54±1664       461 (14-3745.8)         Consulting expenses       261.75±260       42 (0-580.99)         Intensive care       414.78±367       420 (0-780)         Policlinic       148.88±93.14       111 (30-286)				
Operation, anesthesia expenses $19045.74\pm12012$ $18622$ (3650-32678.88)Blood and blood product expenses $1653.54\pm1664$ $461$ (14-3745.8)Consulting expenses $261.75\pm260$ $42$ (0-580.99)Intensive care $414.78\pm367$ $420$ (0-780)Policlinic $148.88\pm93.14$ $111$ (30-286)	Radiology expenses	90.2±45.4		
Image: Construct of the second system $(3650-32678.88)$ Blood and blood product expenses $1653.54\pm1664$ $461$ ( $14-3745.8$ )Consulting expenses $261.75\pm260$ $42$ ( $0-580.99$ )Intensive care $414.78\pm367$ $420$ ( $0-780$ )Policlinic $148.88\pm93.14$ $111$ ( $30-286$ )			· · · · ·	
Blood and blood product expenses       1653.54±1664       461 (14-3745.8)         Consulting expenses       261.75±260       42 (0-580.99)         Intensive care       414.78±367       420 (0-780)         Policlinic       148.88±93.14       111 (30-286)	Operation, anesthesia expenses	19045.74±12012		
Image: Consulting expenses       261.75±260       42         Consulting expenses       261.75±260       42         (0-580.99)       (0-580.99)         Intensive care       414.78±367       420         (0-780)       (0-780)         Policlinic       148.88±93.14       111         (30-286)       (30-286)			· · · · ·	
Consulting expenses       261.75±260       42         (0-580.99)       (0-580.99)         Intensive care       414.78±367       420         (0-780)       (0-780)         Policlinic       148.88±93.14       111         (30-286)       (30-286)	Blood and blood product expenses	1653.54±1664		
(0-580.99)       Intensive care     414.78±367     420       (0-780)       Policlinic     148.88±93.14     111       (30-286)	C II		· · ·	
Intensive care       414.78±367       420 (0-780)         Policlinic       148.88±93.14       111 (30-286)	Consulting expenses	261.75±260		
(0-780) Policlinic 148.88±93.14 111 (30-286)	Tuton sine same	414 78+267		
Policlinic 148.88±93.14 111 (30-286)	Intensive care	414.78±307		
(30-286)	Policlinic	148 88+93 14		
	1 One mile	170.00±73.14		
	Total	23452±16154	20008	
(4799-43308.73)				

## Table 1. Descriptive characteristics of the data

Data are shown as mean±standard deviation or median (minimum-maximum). Expenditure amounts are stated in TL(b).

underwent one-stage revision, and 1027.04  $\clubsuit$  in the patients who underwent two-stage revision (Fig. 1). In the statistical study, it was found to be significant between the groups (P<0.001). The cost difference is thought to be high due to the extended stay in the service and the large number of medical supplies used in patients who underwent two-stage revision.

When the operation and operating room expenses of the patients were compared, it was found that the average of the patients who underwent primary arthroplasty was 5583.21  $\pounds$ , and the patients who underwent one-stage revision were 13301.30  $\pounds$ . In comparison, the average of the patients who underwent two-stage revision was 31592.44  $\pounds$  (Fig. 1). A statistically sig-

	Primary	Aseptic reasons, one- stage revision	Septic reasons, two- stage revisions	P value
Length of stay (days)	3 (2-4)	6 (3-7)	27 (18-49)	<0.001
Surgery time (min)	90 (75-120)	150 (120-180)	270 (180-320)	<0.001
Service expenses	98.98 (78-176)	135.56 (78-350)	1051.31 (467-1210)	<0.001
Drug expenditures	168 (88.9-189)	189 (88.9-3410)	2987.33 (1987-3865)	<0.001
Laboratory expenses	42 (32-56)	46 (32-245)	496 (126-530.79)	<0.001
Radiology expenses	38 (32-46)	40.12 (39.99-150)	135 (110-156)	<0.001
Operation, anesthesia expenses	3890 (3650-4980)	6120 (3650-19769)	31864 (18111-32678)	<0.001
Blood and blood product expenses	14 (14-28)	103 (14-464)	3354.78 (230-3745)	<0.001
Consulting expenses	12 (0-48)	19.37 (0-68)	510 (42-580.99)	<0.001
Intensive care expenses	0	89.36 (0-420)	780 (0-780)	<0.001
Policlinic expenses	49 (30-67)	66.82 (30-131)	216 (49-286)	<0.001
Total	5689 (4799-8294)	8294.97 (4799-21174)	40919.67 (19362-43308)	<0.001

# Table 2. Comparison of primary, aseptic reasons, one-stage revision and septic reasons, two-stage revisions knee arthroplasty data

Data are shown as median (minimum-maximum). Expenditure amounts are stated in TL(b).

nificant difference exists between the groups (P < 0.001). The fact that patients who underwent twostage revision underwent multiple operations and the cost of the revision implants used confirms this difference.

When the pharmacological costs were compared, the mean of the primary arthroplasty group was 141.66  $\pounds$ , and the mean of the patients who underwent onestage revision was 389.17  $\pounds$ . The mean of the patients who underwent two-stage revision was 2964.79  $\pounds$ (Fig. 2). These data were found significant when compared (P<0.001). The high cost of pharmacological agents in two-stage revisions can be attributed to the fact that they received both prophylactic and agentspecific antibiotics during the hospitalization, the lengthening of the hospitalization period, and the increase in the agents used due to additional patients.

When the blood products of the patients were added up, it was found that the average of patients who underwent primary arthroplasty was 34.17 Ł. In comparison, it was 182.96 Ł for the patients who underwent one-stage revision and 3430.19 Ł for those who underwent two-stage revision (Fig. 2). A significant statistical difference was found between the groups (P<0.001). The fact that the cost of blood products of patients who underwent two-stage revision is relatively high indicates that the need for blood product transfusion is high in preparation for the operation, during and after the operation.



Fig. 1. Distribution of significant expenditure items among groups. Expenditure amounts are stated in TL(Ł).



Fig. 2. Comparison of intensive care-blood products-drug cost between groups.

When the intensive care unit expenses of the patients were added up, it was seen that the patients who underwent primary arthroplasty did not need intensive care. While the mean of patients who underwent onestage revision was 177.69  $\pounds$ , it was found to be 780.00  $\pounds$  for patients who underwent two-stage revision (Fig. 2). When the data were compared, it was found to be statistically significant, and it was found that the cost of intensive care increased due to the increase in the number of operations and revision operations being more complex and taking longer (P<0.001).

#### DISCUSSION

As a result of advancing technological opportunities and increasing comfort expectations, the number of hospital applications and operations is rising daily. As a result of the increase in the elderly population, orthopedic prosthesis operations are increasing not only in our country but also worldwide. As a result of the increase in primary arthroplasty operations, revision operations are also increasing in parallel [14-16]. At the same time, the incidence of periprosthetic knee infections is increasing [10]. Managing these infections often requires two-stage revision procedures, which can cost more than mechanical failure and/or aseptic loosening revisions [17].

In our study, we aimed to reveal the cost items of primary arthroplasty and revision operations and to draw attention to the burden on the health system. Two-stage revision costs due to periprosthetic infection were observed to triple the costs of revision procedures due to aseptic loosening. In these infections, the increasing resistance of microorganisms and the ineffectiveness of antibiotic treatments are blamed. For this reason, the doses of antibiotics are increased, and the duration of use is prolonged. Patients require long-term hospitalization, and in some cases, additional operations may be necessary. Therefore, the prevention of periprosthetic infections is essential for reducing health expenditures.

The results of our study were similar to previous studies evaluating the economic impact of surgical site infections following total knee joint arthroplasty [17-20]. Kapadia *et al.*, mean episode cost, length of hospital stay, and median readmissions were significantly higher in the infected group compared to the matched

cohort: \$88,623 to \$25,659, 7.6 to 3.29 days, and 2 to 0. Periprosthetic care after TKA was approximately the cost of the episode. It was caused by a 3-fold, 2-fold increase in the average length of hospital stay and an increase in the median readmission time [20]. Periprosthetic infections following TKA represent a tremendous economic burden for tertiary-care centers and patients [19].

It has been observed in the literature that when it comes to septic-based revision surgery, the cost of blood products and drugs is significantly higher during inpatient treatment [21]. A cost analysis of septic total knee revision surgeries should include all costs covered by the hospital, including two separate hospitalizations for the two-stage revision and personnel costs [22]. This study is important because it takes into account all costs incurred during inpatient treatment covered by the hospital, including hospitalization duration, medication, treatment, surgery, anesthesia, laboratory tests, imaging, blood center services, consultation, visits, meal costs, total costs, and billing expenses. The study found that the costs incurred in the septic group were significantly higher than the aseptic group (P<0.001).

Minimizing the number of revisions per patient is crucial in reducing the overall cost burden of revision. This can be achieved by adopting a comprehensive approach that includes optimal patient selection, prosthesis selection, and procedure selection for primary TKA [23, 24]. Careful evaluation of patient characteristics, such as age, weight, and comorbidities, is necessary to select the most appropriate prosthesis and procedure. In addition to these measures, reducing the number of primary TKA surgeries can be achieved through effective non-operative knee osteoarthritis management. This may include weight management programs to combat obesity, exercise programs to improve joint flexibility and strength, and lifestyle changes to reduce the risk of joint injury. By implementing these strategies, the incidence of revision surgeries can be reduced, and the overall cost burden of TKA can be minimized.

The financial burden of septic revision TKA with re-revision can be significantly higher, up to 2.5 times, compared to septic revision alone. Similarly, it can be up to 4 times higher than aseptic revision when re-revision is not required. However, cost savings can be realized by minimizing the occurrence of primary TKA that develop PJI, avoiding re-revisions for PJI, and shortening the length of hospitalization following revision surgery [25].

## Limitations

This study has some limitations. Differences in patients' socioeconomic status may have introduced confounding factors among cohorts, leading to an overor underestimation of inconsistencies in costs, number of readmissions, and length of hospitalization. However, to minimize any potential bias, patients were selected into groups and matched with the help of a computer-aided program according to the type of surgical procedure, date of surgery, age, and gender parameters. Other limitations are the short follow-up period, the small number of subjects, and the study's retrospective nature. Longer follow-up, larger sample sizes, and prospective multicenter studies are needed to analyze this patient population better. In light of the COVID pandemic, many countries, including Turkey, have been experiencing economic difficulties. It has been observed that the costs of many healthcare practices, materials and revision knee arthroplasty have increased over the years [26, 27]. However, it is important to note that the study conducted had a limitation in terms of fair cost distribution between groups based on the number of years, as it was a direct cost comparison study. Due to these limitations, the real economic and personal impact seen in the cohort undergoing two-stage revision surgery may be more significant than it is.

## CONCLUSION

Preventing and treating periprosthetic infections is costly and challenging. We need more research to develop effective protocols and reduce costs. As the number of patients undergoing knee arthroplasty is expected to rise, healthcare systems must ensure the sustainability of public financial resources, especially in public university hospitals.

## Ethics approval

This retrospective study was conducted with the approval of the Ondokuz Mayıs University clinical research ethics committee (approval number: E-15374210-010.06.99-349814). Institutional Review

Board approval and informed consent of the patients were obtained.

## The institution where the study was carried out

Department of Orthopaedics and Traumatology,

Ondokuz Mayis University Hospital, Samsun, Türkiye

#### Authors' Contribution

Study Conception: AY, FS; Study Design: AY; Supervision: FS; Funding: N/A; Materials: AE, CŞŞ; Data Collection and/or Processing: AY, AE, CŞŞ; Statistical Analysis and/or Data Interpretation: AY, AE, CŞŞ; Literature Review: AY, AE; Manuscript Preparation: AY, AE, CŞŞ and Critical Review: AY, AE, FS.

## Conflict of interest

The authors disclosed no conflict of interest during the preparation or publication of this manuscript.

#### Financing

The authors disclosed that they did not receive any grant during conduction or writing of this study.

## REFERENCES

1. Long H, Liu Q, Yin H, et al. Prevalence Trends of Site-Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019. Arthritis Rheumatol. 2022;74(7):1172-1183. doi: 10.1002/art.42089.

2. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;27(8 Suppl):61-65.e1. doi: 10.1016/j.arth.2012.02.022. 3. Klug A, Gramlich Y, Rudert M, et al. The projected volume of primary and revision total knee arthroplasty will place an immense burden on future health care systems over the next 30 years. Knee Surg Sports Traumatol Arthrosc. 2021;29(10):3287-3298. doi: 10.1007/s00167-020-06154-7.

4. Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014;27(2):302-345. doi: 10.1128/CMR.00111-13.

5. Gbejuade HO, Lovering AM, Webb JC. The role of microbial biofilms in prosthetic joint infections. Acta Orthop. 2015;86(2):147-158. doi: 10.3109/17453674.2014.966290.

6. Leonard HA, Liddle AD, Burke O, Murray DW, Pandit H. Single- or two-stage revision for infected total hip arthroplasty? A systematic review of the literature. Clin Orthop Relat Res. 2014;472(3):1036-1042. doi: 10.1007/s11999-013-3294-y.

7. Kurtz SM, Ong KL, Schmier J, et al. Future clinical and economic impact of revision total hip and knee arthroplasty. J Bone Joint Surg Am. 2007;89 Suppl 3:144-151. doi: 10.2106/JBJS.G.00587.

8. Senthi S, Munro JT, Pitto RP. Infection in total hip replacement: meta-analysis. Int Orthop. 2011;35(2):253-260. doi: 10.1007/s00264-010-1144-z.

9. Whitehouse JD, Friedman ND, Kirkland KB, Richardson WJ, Sexton DJ. The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol. 2002;23(4):183-189. doi: 10.1086/502033.

10. Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty. 2008;23(7):984-991. doi: 10.1016/j.arth.2007.10.017. 11. Parvizi J, Pawasarat IM, Azzam KA, Joshi A, Hansen EN, Bozic KJ. Periprosthetic joint infection: the economic impact of methicillin-resistant infections. J Arthroplasty. 2010;25(6 Suppl):103-107. doi: 10.1016/j.arth.2010.04.011.

12. Bonnin M, Deschamps G, Neyret P, Chambat P. [Revision in non-infected total knee arthroplasty: an analysis of 69 consecutive cases]. Rev Chir Orthop Reparatrice Appar Mot. 2000;86(7):694-706. [Article in French].

13. Sousa R, Ribau A, Alfaro P, et al. The European Bone and Joint Infection Society definition of periprosthetic joint infection is meaningful in clinical practice: a multicentric validation study with comparison with previous definitions. Acta Orthop. 2023;94:8-18. doi: 10.2340/17453674.2023.5670.

14. Barret M WE, Whalen D. Summary 2007 HCUP Nationwide Inpatient Sample (NIS) Comparison Report. HCUP Method Series Report # 2010-03. Online September 9, 2010. U.S. Agency for Healthcare Research and Quality.

15. Ollenschläger G. Assuring the Quality of Health Care in the EU: Germany. In book: Assuring the Quality of Health Care in the European Union. A case for action. Ed.: European Observatory Studies Series Nr 12, WHO Publication: Copenhagen, 2008: pp. 116-120.

16. Mark Allen Group. Hospital non-compliance risking joint patient safety. Br J Hosp Med. 2012;73(10):548. doi: 10.12968/hmed.2012.73.10.548a.

17. Bozic KJ, Ries MD. The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization. J Bone Joint Surg Am. 2005;87(8):1746-1751. doi: 10.2106/JBJS.D.02937. 18. Hebert CK, Williams RE, Levy RS, Barrack RL. Cost of treat-

ing an infected total knee replacement. Clin Orthop Relat Res. 1996;(331):140-145. doi: 10.1097/00003086-199610000-00019. 19. Kapadia BH, McElroy MJ, Issa K, Johnson AJ, Bozic KJ, Mont MA. The economic impact of periprosthetic infections following total knee arthroplasty at a specialized tertiary-care center. J Arthroplasty. 2014;29(5):929-932. doi: 10.1016/j.arth.2013.09.017.

20. Kapadia BH, Banerjee S, Cherian JJ, Bozic KJ, Mont MA. The Economic Impact of Periprosthetic Infections After Total Hip Arthroplasty at a Specialized Tertiary-Care Center. J Arthroplasty. 2016;31(7):1422-1426. doi: 10.1016/j.arth.2016.01.021.

21. Dırvar F, Dırvar SU, Yıldırım T, Cengiz Ö, Talmaç MA. Cost Analysis in Knee Revision Arthroplasty: A Study at the Research and Training Hospital in Turkey. JAREM J Acad Res Med. 2020;10(2):133-137. doi: 10.4274/jarem.galenos.2020.2767.

22. Kasch R, Merk S, Assmann G, et al. Comparative Analysis of Direct Hospital Care Costs between Aseptic and Two-Stage Septic Knee Revision. PLoS One. 2017;12(1):e0169558. doi: 10.1371/journal.pone.0169558.

23. Vertullo CJ, Graves SE, Peng Y, Lewis PL. An optimum prosthesis combination of low-risk total knee arthroplasty options in all five primary categories of design results in a 60% reduction in revision risk: a registry analysis of 482,373 prostheses. Knee Surg Sports Traumatol Arthrosc. 2019;27(5):1418-1426. doi: 10.1007/s00167-018-5115-z.

24. Adie S, Harris I, Chuan A, Lewis P, Naylor JM. Selecting and optimising patients for total knee arthroplasty. Med J Aust. 2019;210(3):135-141. doi: 10.5694/mja2.12109.

25. Okafor C, Hodgkinson B, Nghiem S, Vertullo C, Byrnes J. Cost of septic and aseptic revision total knee arthroplasty: a systematic review. BMC Musculoskelet Disord. 2021;22(1):706. doi: 10.1186/s12891-021-04597-8.

26. Ashkenazi I, Christensen T, Ward SA, et al. Trends in Revenue and Cost for Revision Total Knee Arthroplasty. J Arthroplasty. 2023;38(7 Suppl 2):S97-S102. doi: 10.1016/j.arth.2023.01.041.

27. Lopez-Villegas A, Bautista-Mesa RJ, Acosta-Robles P, et al. Analysis of Healthcare Costs Incurred in Regional Hospitals in Andalusia (Spain) during the COVID-19 Pandemic. Int J Environ Res Public Health. 2022;19(23):16132. doi: 10.3390/ijerph192316132.